Sonova Stock Surges After UBS Upgrade to 'Buy'

Shares of Sonova (SOON) surged as much as 6.0% on Tuesday after analysts at UBS upgraded the Swiss hearing-care manufacturer to 'Buy' from 'Neutral.' The bank also raised its price target on the stock to CHF 242 from a previous CHF 206, signaling significant potential upside.

The Catalyst: A Decisive Upgrade

The upgrade from UBS was a key driver for the stock's performance, pushing its price to CHF 212.4 in a market where broader indices were trading lower. The bank's note pointed to several factors that informed its more bullish stance on the company and the hearing-care sector as a whole.

According to UBS, Sonova's valuation has become particularly compelling. The bank noted that the company's valuation relative to its Danish peer, William Demant, has reached its most attractive point since 2021, making Sonova its preferred name in the space.

Sector Strength and Market Context

Ad

UBS's rationale extends beyond Sonova's individual metrics, highlighting the strength of the broader hearing aid market. Key points from the bank's analysis include:

• Recent Outperformance: The hearing aid sector has outperformed the wider European Medtech industry by more than 20% over the past three months.
• Defensive Positioning: The industry is considered relatively insulated from many of the headwinds affecting the broader healthcare market.
• Innovation: The sector is benefiting from growing exposure to artificial intelligence in device development.

Sonova's rally was company-specific and occurred despite a negative backdrop in U.S. equity markets. The move lifts the stock further from its 52-week low of CHF 163, with the new price target approaching its 52-week high of CHF 245.7.